Clinical trials: Non Alcoholic Fatty Liver
Compensated Cirrhosis, Nonalcoholic Steatohepatitis
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
The primary objective of this study is to evaluate whether obeticholic acid (OCA; INT-747) can lead to histological improvement in fibrosis with no worsening of NASH in adults with compensated cirrhosis due to NASH.
- Trial name
- REVERSE (NCT03439254)
- Testing
- Obeticholic acid (10 mg), Obeticholic acid (10 mg to 25 mg)
- Where
- 192 sites in United States, Australia and 10 more
- Volunteers
- 919 people
- Sponsor
- Intercept Pharmaceuticals
HIV, Fatty Liver
Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients
People infected with HIV are living longer thanks to the use of antiretroviral therapy (cART). In aging HIV persons, other factors are associated with early death.
- Conditions
- HIV, Fatty Liver, Nonalcoholic Steatohepatitis
- Trial name
- NCT02210715
- Testing
- Isentress., Continue usual antiretroviral therapy
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Obesity
South Danish Obesity Initiative, Screening for Unrecognized Obesity Related Disease
People with BMI >30 kg/m2 will be included in at population-based cohort. Additionally, one control group with BMI 18.5-25 kg/m2 and one control group with BMI 25-30 kg/m2 will be included.
- Trial name
- SDOI (NCT05176132)
- Testing
- Life style intervention (dietician+ physiotherapist), Self management, No intervention
- Where
- Denmark
- Volunteers
- 2,700 people, healthy volunteers welcome
- Sponsor
- Claus Bogh Juhl
Non-Alcoholic Fatty Liver Disease
Pilot of Lifestyle Behavior Intervention for Non-Alcoholic Fatty Liver Disease
The purpose of this study is to pilot test a behavioral lifestyle intervention for Hispanic/Latino patients with non-alcoholic fatty liver disease (NAFLD)
- Trial name
- NCT05200585
- Testing
- Healthy Liver/Hígado Sano program, Usual standard of care
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- The University of Texas Health Science Center, Houston
NAFLD, Liver Cirrhosis
Risk Factors for Advanced Fibrosis Among FLD Patients
The investigators investigate the heterogeneity fatty liver disease (FLD) as well as risk factors associated with progression of the liver diseases or development of cardiovascular complication.
- Conditions
- NAFLD, Liver Cirrhosis, Diabetes Mellitus, Type 2
- Trial name
- FLD_FU_HUS (NCT05971082)
- Testing
- Follow-up
- Where
- Finland
- Volunteers
- 1,000 people
- Sponsor
- Helsinki University Central Hospital
Non-Alcoholic Fatty Liver Disease
Effect of Indo-Mediterranean Diet on Hepatic Steatosis and Fibrosis in NAFLD Children
NAFLD encompasses the entire spectrum of Fatty liver disease in individuals without significant alcohol consumption, ranging from fatty liver to steatohepatitis to cirrhosis.
- Trial name
- NCT05073588
- Testing
- Indo Mediterranean diet, Calorie restricted diet
- Where
- India
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Institute of Liver and Biliary Sciences, India
NAFLD, Web
Web-based Interventions on Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Children
The web-based continuity of care intervention model to provide comprehensive nursing interventions for obese children with NAFLD, always tracking their performance status, enabling them to grasp the knowledge of healthy weight…
- Conditions
- NAFLD, Web, Childhood Obesity
- Trial name
- NCT05527938
- Testing
- web-based intervention
- Where
- China
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Shaoxing Maternity and Child Health Care Hospital
Non Alcoholic Fatty Liver Disease
UDFF Performance Evaluation ((Ultrason Derived Fat Fraction)
The purpose of this study is to assess UDFF performance (compared to MRI)
- Trial name
- UDFF (NCT06080386)
- Testing
- UDFF
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Angers
Non-alcoholic Steatohepatitis (MASH), Non-alcoholic Fatty Liver Disease (MASLD)
Barriers to MASLD Management in Europe: Findings From a Multidisciplinary HCP-survey
The purpose of this study is to better understand the main barriers to earlier diagnosis and better management of MASLD/MASH patients and to understand the key barriers to adoption of guidelines.
- Trial name
- BARRIERS-MASLD (NCT05765890)
- Testing
- No treatment given
- Where
- India
- Volunteers
- 675 people
- Sponsor
- Novo Nordisk A/S
Fatty Liver Disease
Effect of Thyroid Disorders in Liver Diseases
Aims of the Research 1. To detect correlation between hyperthyroidism and non alcoholic fatty liver disease (NAFLD). 2. To detect hepatic risk in subclinical and clinical hypothyroidism . 3.
- Trial name
- NCT06071923
- Testing
- Fibroscan
- Volunteers
- 140 people
- Sponsor
- Assiut University
NAFLD
Probiotic Supplementation IN NAFLD Patients
this study aimed to evaluate the effectiveness of Probiotics supplementation (lactobacillus) on NAFLD fibrosis score.
- Trial name
- NCT06074094
- Testing
- Control Test
- Where
- Egypt
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
The purpose of this study is to directly characterize the pharmacokinetic (PK) profiles of MGL-3196 and its major metabolite (MGL-3623) following administration of multiple oral doses (QD x 6 days) in subjects with varying…
- Conditions
- Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver
- Trial name
- NCT04643795
- Testing
- MGL-3196
- Where
- 3 sites in United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
Non-Alcoholic Fatty Liver Disease in a Saudi Cohort With Type 2 Diabetes Mellitus
The global rise in the prevalence of obesity paved the way for the increased prevalence of yet another obesity-related complication significant enough to be considered within the roster of major public health threats…
- Trial name
- CORDIAL (NCT05697991)
- Where
- Saudi Arabia
- Volunteers
- 1,000 people
- Sponsor
- King Saud University
Non-Alcoholic Fatty Liver Disease, Bariatric Surgery
Liver Fat Content and Bariatric Surgery
On the basis of previous research, this subject intends to evaluate the liver improvement of patients with liver disease after weight loss by MRI, and quantify it by extracting features, so as to provide a new method to judge the…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Bariatric Surgery, Magnetic Resonance Imaging
- Trial name
- NCT06064240
- Testing
- We do not have any intervention type
- Where
- China
- Volunteers
- 50 people
- Sponsor
- yu li，MD
Schizophrenia, Treatment-resistant Schizophrenia
Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis
SchizOMICS is a Phase IV, multicenter, dose-flexible, open-label, randomized controlled clinical trial to evaluate the efficacy and safety of aripiprazole versus paliperidone using multi-omics data in patients with a first…
- Conditions
- Schizophrenia, Treatment-resistant Schizophrenia, Side Effect, Lipid Metabolism Disorders
- Trial name
- SchizOMICS (NCT06060886)
- Testing
- Aripiprazole, Paliperidone
- Volunteers
- 244 people
- Sponsor
- Consorcio Centro de Investigación Biomédica en Red (CIBER)
Obesity, Non-Alcoholic Fatty Liver Disease
Effect of Timed-Restricted Eating on Metabolic Health
We aim to determine the effect of combined isocaloric time restricted eating and meal timing on metabolic health, liver fat, functional brain networks, inflammation, and sleep pattern/quality in subjects with obesity and insulin…
- Conditions
- Obesity, Non-Alcoholic Fatty Liver Disease, Insulin Resistance
- Trial name
- TREAT (NCT06061042)
- Testing
- Early time restricted eating, Late time restricted eating
- Where
- Netherlands
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
NASH - Nonalcoholic Steatohepatitis
A Study of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia
A Randomized Study of ALG-055009 Drug to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses in Healthy Volunteers and Subjects with Hyperlipidemia
- Trial name
- NCT05090111
- Testing
- ALG-055009
- Where
- France
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Aligos Therapeutics
Non-Alcoholic Fatty Liver Disease
Ectopic Fat in Singaporean Women - the Culprit Leading to Gestational Diabetes, Metabolic Syndrome, and Type 2 Diabetes (TANGO Study)
Ectopic fat is the accumulation of adipose tissue in anatomical sites not classically associated with fat storage - for example, in the liver and skeletal muscles.
- Trial name
- TANGO (NCT05259475)
- Testing
- Lifestyle Advice, Diet Intervention, OCFA Meal-Based Diet-Intervention
- Where
- Singapore
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Institute for Human Development and Potential (IHDP), Singapore
Non-alcoholic Fatty Liver, Atherogenic Dyslipidemia
Genetic Pathways Leading to Fatty Liver and Atherogenic Dyslipidemia
The aims of the study are: 1. To investigate if carriers of apolipoprotein (apo) CIII loss-of-function (LOF) mutations produce less apo-CIII that results in reduction of large very low-density lipoprotein (VLDL) particle…
- Conditions
- Non-alcoholic Fatty Liver, Atherogenic Dyslipidemia, Insulin Resistance
- Trial name
- VARKIN (NCT04209816)
- Testing
- Lipoprotein kinetics
- Where
- 2 sites in Finland, Sweden
- Volunteers
- 100 people
- Sponsor
- Marja-Riitta Taskinen
Type 2 Diabetes, NAFLD
Nutraceutical Improvement of Glucose Metabolism, NAFLD and Insulin Resistance by Oat-fiber Supplementation in Type 2 Diabetes Mellitus Patients
Cohort studies show an association between increased intake of insoluble (cereal) fiber and decreased risk for cardiovascular disease, type 2 diabetes (T2DM), non-alcoholic fatty liver disease (NAFLD), cancer, infectious and…
- Trial name
- NIMROD (NCT05654805)
- Testing
- Drinking powder supplement
- Where
- Germany
- Volunteers
- 92 people
- Sponsor
- Charite University, Berlin, Germany